Tissue factor in antiphospholipid syndrome: Shifting the focus from coagulation to endothelium

Rheumatology

Volumn 42, Issue 9, 2003, Pages 1029-1031

  Amengual, O ^a   Atsumi, T ^a   Khamashta, Munther A ^b  

^a HOKKAIDO UNIVERSITY   (Japan)

^b ST THOMAS HOSPITAL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ANTITHROMBOCYTIC AGENT; AUTOANTIBODY; FLUINDOSTATIN; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; PHOSPHOLIPID ANTIBODY; PLASMA PROTEIN; PROTEIN ANTIBODY; RECOMBINANT PROTEIN; RECOMBINANT THROMBOPLASTIN; SIMVASTATIN; THROMBOPLASTIN;

ANTICOAGULANT THERAPY; ANTIPHOSPHOLIPID SYNDROME; BLOOD CLOTTING; CELL INTERACTION; CLINICAL FEATURE; DRUG EFFICACY; EDITORIAL; ENDOTHELIUM; ENDOTHELIUM CELL; HUMAN; MEDICAL RESEARCH; PATHOGENESIS; PATHOPHYSIOLOGY; PREGNANCY DISORDER; PRIORITY JOURNAL; SIGNAL TRANSDUCTION; THROMBOSIS; TREATMENT PLANNING;

ANTIPHOSPHOLIPID SYNDROME; BLOOD COAGULATION; ENDOTHELIUM, VASCULAR; HUMANS; THROMBOPLASTIN; THROMBOSIS;

EID: 0141615860     PISSN: 14620324     EISSN: None     Source Type: Journal    
DOI: 10.1093/rheumatology/keg273     Document Type: Editorial

References (17)

1. Khamashta MA. Hughes syndrome: Antiphospholipid syndrome. In: Khamashta MA, ed. Hughes syndrome: history. London: Springer-Verlag, 2000:3-7.
2. Ieko M, Ichikawa K, Triplett D et al. Beta2-glycoprotein I is necessary to inhibit protein C activity by monoclonal anticardiolipin antibodies. Arthritis Rheum 1999; 42:167-74.
3. Takeuchi R, Atsumi T, Ieko M et al. Coagulation and fibrinolytic activities in 2 siblings with β2-glycoprotein I deficiency. Blood 2000;96:1594-5.
4. Mann K. Biochemistry and physiology of blood coagulation. Thromb Haemost 1999;82:165-74.
5. Kornberg A, Blank M, Kaufman S, Shoenfeld Y. Induction of tissue factor-like activity in monocytes by anti-cardiolipin antibodies. J Immunol 1994;153:1328-32.
6. Atsumi T, Khamashta MA, Amengual O, Hughes GRV. Up-regulated tissue factor expression in antiphospholipid syndrome. Thromb Haemost 1997;77:222-3.
7. Cuadrado MJ, Lopez-Pedreira C, Khamashta MA et al. Thrombosis in primary antiphospholipid syndrome. A pivotal role for monocyte tissue factor expression. Arthritis Rheum 1997;40:834-41.
8. Amengual O, Atsumi T, Khamashta MA, Hughes GRV. The role of the tissue factor pathway in the hypercoagulable state in patients with the antiphospholipid syndrome. Thromb Haemost 1998;79:276-81.
9. Del PaPa N, Guidali L, Sala A et al. Endothelial cells as target for antiphospholipid antibodies. Arthritis Rheum 1997;40:551-61.
10. Arnout J. The pathogenesis of the antiphospholipid syndrome: a hypothesis based on parallelisms with heparin-induced thrombocytopenia. Thromb Haemost 1996;75:536-41.
11. Pierangeli S, Espinola R, Liu X, Harris E, Salmon J. Identification of an Fc gamma receptor independent mechanism by which intravenous immunoglobulin ameliorates antiphospholipid antibody-induced thrombogenic phenotype. Arthritis Rheum 2001;44:876-83.
12. Zhou H, Roubey RAS. Annexin A2 and antiphospholipid-antibody induced upregulation of monocyte tissue factor. Arthritis Rheum 2002;46:S232.
13. Dunoyer-Geindre S, De Moerloose P, Galve-De Rochemonteix B, Reber G, Kruithof E. NFkappaB is an essential intermediate in the activation of endothelial cells by anti-beta(2)-glycoprotein 1 antibodies. Thromb Haemost 2002;88:851-7.
14. Rapaport SI. Regulation of the tissue factor pathway. Ann NY Acad Sci 1991;614:51-62.
15. Bajaj M, Bajaj S. Tissue factor pathway inhibitor: potential therapeutic applications. Thromb Haemost 1997; 78:471-7.
16. Meroni P, Raschi E, Testoni C et al. Statins prevent endothelial cell activation induced by antiphospholipid (anti-beta2-glycoprotein I) antibodies: effect on the proadhesive and proinflammatory phenotype. Arthritis Rheum 2001;44:2870-8.
17. Ferrara DE, Swerlick R, Harris EN, Meroni PL, Pierangeli S. Fluvastatin inhibits upregulation of tissue factor expression by antiphospholipid antibodies on endothelial cells. Arthritis Rheum 2002; 46:S232.